Special Issue "Cystic Fibrosis: Genetics, Pathophysiology and Novel Therapeutic Approaches"
A special issue of Journal of Respiration (ISSN 2673-527X).
Deadline for manuscript submissions: 31 December 2021.
Interests: nose-to-brain delivery; applications of nanoparticles to drug delivery; Parkinson Disease; mucopenetration; mesenchymal stem cells; exosomes; airway diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue in Molecules: Plant-Derived Phenolic Compounds: From Molecular Mechanisms to Clinical Application
Special Issue in Pharmaceutics: Polymer- and Lipid-Based Nanostructured Drug Delivery Systems for the Treatment of CNS Diseases: Recent Advances towards Clinical Application
Cystic fibrosis (CF) is a life-threatening autosomal recessive disorder due to mutations in the CF Transmembrane Conductance Regulator (CFTR) gene that cause morbidity and mortality mainly by inducing lung disease. This Special Issue is devoted to appraising the most recent developments in CF research and its clinical facets, focusing on the fields of genetics, theranostics, immunology, infections, inflammation, and novel therapeutic approaches. It will present genotype/phenotype correlations, rare mutations, and modifier genes of CF lung disease—one of the most interesting genetic aspects under intense study. Established pathophysiologic hallmarks of CF lung disease are opportunistic bacterial infections and heightened inflammatory response. Research is now focused on both the involvement of other ion channel/transporters and the host innate and adaptive immune response. In the coronavirus 2019 (COVID-19) era, the natural history of CF pathophysiology is changing, thereby this Special Issue will be insightful in discussing how the present pandemic infection could determine other clinical features in CF patients. Finally, basic and applied research have sought and identified etiological treatments for CF, highlighted by the clinical use of modulators (potentiators, correctors) of the mutated CFTR protein. Novel genetic and stem cell-based treatments as potential therapeutic approaches to cure CF are at the forefront of CF research and will be also covered in this Special Issue.
Prof. Dr. Massimo Conese
Dr. Onofrio Laselva
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Respiration is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cystic fibrosis
- CFTR genotype
- modifier genes
- ion channels/transporters
- immune cells
- extracellular vesicles
- CFTR modulators
- gene editing
- stem cells